financetom
Business
financetom
/
Business
/
Crescent Capital BDC reports Q2 net investment income of $0.46/share
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Crescent Capital BDC reports Q2 net investment income of $0.46/share
Aug 13, 2025 1:48 PM

Overview

* Crescent Capital BDC ( CCAP ) Q2 net investment income at $0.46/share, net income $0.41/share

* Net asset value per share declined to $19.55 from $19.62 in prior qtr

* Co authorizes $20 mln stock repurchase program below NAV

Result Drivers

* INVESTMENT INCOME - Increase in investment income to $43.0 mln, driven by higher dividend income from Logan JV

* PORTFOLIO ACTIVITY - Invested $57.5 mln in new companies and had $92.7 mln in exits, sales, and repayments

* DIVIDEND INCREASE - Dividend income rose to $1.8 mln from $1.5 mln in the previous qtr

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS $0.46

Q2 $1.60

Investme bln

nts Fair

Value

Q2 Net $19.55

Asset

Value

Per

Share

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the closed end funds peer group is "buy"

* Wall Street's median 12-month price target for Crescent Capital BDC Inc ( CCAP ) is $17.00, about 14.1% above its August 12 closing price of $14.60

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket
Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket
Feb 24, 2025
07:43 AM EST, 02/24/2025 (MT Newswires) -- Entrada Therapeutics ( TRDA ) said Monday that the US Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and cleared the company's plan to start a phase 1b study of the product candidate as a potential treatment for adults with Duchenne muscular dystrophy or DMD. The company said the 1b...
Orezone Gold to Accelerate Bombore Stage II Hard Rock Expansion, to List on Australia's ASX
Orezone Gold to Accelerate Bombore Stage II Hard Rock Expansion, to List on Australia's ASX
Feb 24, 2025
07:45 AM EST, 02/24/2025 (MT Newswires) -- Orezone Gold ( ORZCF ) , trading at a 52-week high, on Monday said it is accelerating production growth and exploration at its Bombore Gold Mine in Burkina Faso. The company also said it will list on the Australian Securities Exchange in the middle of this year. Orezone will accelerate Stage II of...
Domino's Pizza Q4 Same Store Sales Growth Lags, Proposes 15% Dividend Hike
Domino's Pizza Q4 Same Store Sales Growth Lags, Proposes 15% Dividend Hike
Feb 24, 2025
Domino’s Pizza Inc.  shares are trading lower in premarket on Monday after the fourth-quarter FY24 earnings result. The company reported fourth-quarter sales growth of 2.9% year-on-year to $1.44 billion, missing the analyst consensus estimate of $1.48 billion. The revenue increase was primarily due to higher supply chain and U.S. franchise advertising revenues.  The growth in supply chain revenues was attributable to...
Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA
Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA
Feb 24, 2025
07:46 AM EST, 02/24/2025 (MT Newswires) -- Invivyd ( IVVD ) said Monday that the US Food and Drug Administration rejected its request to expand the existing emergency use authorization for Pemgarda to include treatment of mild-to-moderate Covid-19 in immunocompromised adults and adolescents. The drug, also called pemivibart, is already being used as a preventative measure for some immunocompromised patients...
Copyright 2023-2026 - www.financetom.com All Rights Reserved